Pediatrix Medical Group (FRA:PDC) YoY EBITDA Growth: 2.98% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PDC Pediatrix Medical Group Inc FRA:PDC
54 GF Score
Price €22.40
GF Value €11.53
! 7 Warning Signs
View Full Analysis

What is Pediatrix Medical Group YoY EBITDA Growth?

Pediatrix Medical Group FRA:PDC 54 YoY EBITDA Growth is 2.98% as of Jun. 2026. GuruFocus rates FRA:PDC with a GF Score™ of 54/100 and a GF Value™ of €11.53. The stock has 7 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Pediatrix Medical Group's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 2.98%.

Pediatrix Medical Group's EBITDA per Share for the three months ended in Jun. 2026 was €0.73.

Pediatrix Medical Group YoY EBITDA Growth Related Terms

Pediatrix Medical Group YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Pediatrix Medical Group's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pediatrix Medical Group YoY EBITDA Growth Chart

Pediatrix Medical Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 69.03 -27.77 -81.06 -197.60 944.92

Pediatrix Medical Group Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 142.49 129.28 6.49 20.17 2.98
FRA:PDC
54GF Score
Pediatrix Medical Group Inc FRA:PDC
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pediatrix Medical Group YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Pediatrix Medical Group's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(2.746--0.325)/ | -0.325 |
=944.92 %

Pediatrix Medical Group's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(0.725-0.704)/ | 0.704 |
=2.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 2.98% mean?
Pediatrix Medical Group (FRA:PDC) has a YoY EBITDA Growth of 2.98% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Pediatrix Medical Group and its competitors.
Is Pediatrix Medical Group's YoY EBITDA Growth too high?
Pediatrix Medical Group's current YoY EBITDA Growth is 2.98%. Overall, Pediatrix Medical Group has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does Pediatrix Medical Group's YoY EBITDA Growth compare to ADUS and AVAH?
Pediatrix Medical Group's YoY EBITDA Growth of 2.98% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Healthcare Providers & Services company?
A good YoY EBITDA Growth depends on the Healthcare Providers & Services industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Pediatrix Medical Group and its competitors. Pediatrix Medical Group's current YoY EBITDA Growth is 2.98%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pediatrix Medical Group stock overvalued right now?
Pediatrix Medical Group (FRA:PDC) has a current YoY EBITDA Growth of 2.98%. The stock's GF Value™ is €11.53, compared to a current price of €22.40 — trading 94.3% above its estimated fair value. The current YoY EBITDA Growth is 2.98%. Pediatrix Medical Group's overall GF Score™ is 54/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Pediatrix Medical Group (FRA:PDC), the current YoY EBITDA Growth is 2.98% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pediatrix Medical Group (FRA:PDC) Overvalued in 2026?

Based on GuruFocus' analysis, Pediatrix Medical Group stock appears to be overvalued. The current stock price of €22.40 is trading 94.3% above its estimated GF Value™ of €11.53.

Key valuation signals for FRA:PDC:

  • YoY EBITDA Growth: 2.98%
  • GF Value™: €11.53 vs. price of €22.40 (94.3% above fair value)
  • GF Score™: 54/100 with 7 warning signs

No single metric tells the full story. See the FRA:PDC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pediatrix Medical Group Business Description

Other Exchanges MD:USA
Address 1301 Concord Terrace, Sunrise, FL, USA, 33323
Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.
54GF Score

Get the complete analysis for FRA:PDC

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€22.40
Price
€11.53
GF Value